Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Crippa, José Alexandre de Souza; Pacheco, Juliano Abreu; Zuardi, Antônio Waldo; Guimarães, Francisco Silveira; Campos, Alline C.; Osório, Flávia de Lima; Loureiro, Sônia Regina; Santos, Rafael G. dos; Souza, José Diogo S.; Ushirohira, Juliana Mayumi; Ferreira, Rafael; Costa, Karla Cristinne Mancini; Scomparin, Davi Silveira; Scarante, Franciele Franco; Pires-Dos-Santos, Isabela; Mechoulam, Raphael; Kapczinski, Flávio; Fonseca, Benedito Antônio Lopes da; Espósito, Danillo Lucas Alves; Passos, Afonso Dinis Costa; Fabbro, Amaury Lélis Dal; Bellíssimo-Rodrigues, Fernando; Arruda, Eurico; Scarpelini, Sandro; Andraus, Maristela Haddad; Nather, Júlio César; Wada, Danilo Tadao; Koenigkam-Santos, Marcel; Santos, Antônio Carlos dos; Filho, Geraldo Busatto; Hallak, Jaime Eduardo Cecílio

doi:10.1089/can.2021.0093

Cited by 29 publications

(21 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, only two reports have been conducted on humans. One of the studies reported that CBD administration in COVID-19 patients failed to prevent the deterioration of the clinical status of COVID-19 symptoms [ 50 ], whereas the other study reported that CBD administration in healthcare workers during the COVID-19 pandemic could reduce the symptoms of burnout and emotional exhaustion [ 51 ]. This means that there is no evidence that CBD can prevent or reduce SARS-CoV-2 infection or severity in human studies, but it might be effective for reducing pandemic-related stress.…”

Section: Discussionmentioning

confidence: 99%

The Prevalence of Dietary Supplement Use for the Purpose of COVID-19 Prevention in Japan

Chiba

Tanemura

2022

Nutrients

View full text Add to dashboard Cite

COVID-19 is still the biggest issue worldwide. Many dietary supplements on the market claim to have anti-COVID-19 effects without scientific evidence. To elucidate the prevalence of dietary supplement usage for the prevention of COVID-19, we conducted an online cross-sectional questionnaire survey among Japanese adults in January 2022. The prevalence of dietary supplement use for the prevention of COVID-19 was 8.3%, and there was no gender difference. We also conducted additional research on these dietary supplement users (1000 males and 1000 females). The most popular ingredient used was vitamin C (61.0%), with vitamin D (34.9%) and probiotics (33.4%) following. Half of these participants reported using supplements for more than one year. The information sources that reportedly led them to start using dietary supplements for the prevention of COVID-19 were the Internet (44.0%), television and radio (29.9%), and family or friends (26.0%), and these information sources differed among generations. In conclusion, some of the population used vitamin/mineral supplements for the prevention of COVID-19 that might be beneficial for their health, but some used ingredients with no scientifically proven effects against the virus at this time. Therefore, information-based scientific evidence is important to prevent the inappropriate use of dietary supplements by consumers.

show abstract

Section: Discussionmentioning

confidence: 99%

The Prevalence of Dietary Supplement Use for the Purpose of COVID-19 Prevention in Japan

Chiba

Tanemura

2022

Nutrients

View full text Add to dashboard Cite

show abstract

“…Phytocannabinoids might indirectly relieve the disease progress of COVID-19 patients through their anti-inflammatory properties [266]. However, CBD failed to alter the clinical disease development of COVID-19 when given at a daily dose of 300 mg for 14 days [267]. Additionally, caution should be taken into account due to the immunosuppressive activities of phytocannabinoids that can prevent proper anti-viral immune responses [268].…”

Section: Anti-viral Activities Of Phytocannabinoidsmentioning

confidence: 99%

Anti-Microbial Activity of Phytocannabinoids and Endocannabinoids in the Light of Their Physiological and Pathophysiological Roles

Sionov

Steinberg

2022

Biomedicines

View full text Add to dashboard Cite

Antibiotic resistance has become an increasing challenge in the treatment of various infectious diseases, especially those associated with biofilm formation on biotic and abiotic materials. There is an urgent need for new treatment protocols that can also target biofilm-embedded bacteria. Many secondary metabolites of plants possess anti-bacterial activities, and especially the phytocannabinoids of the Cannabis sativa L. varieties have reached a renaissance and attracted much attention for their anti-microbial and anti-biofilm activities at concentrations below the cytotoxic threshold on normal mammalian cells. Accordingly, many synthetic cannabinoids have been designed with the intention to increase the specificity and selectivity of the compounds. The structurally unrelated endocannabinoids have also been found to have anti-microbial and anti-biofilm activities. Recent data suggest for a mutual communication between the endocannabinoid system and the gut microbiota. The present review focuses on the anti-microbial activities of phytocannabinoids and endocannabinoids integrated with some selected issues of their many physiological and pharmacological activities.

show abstract

“…( Kayser, et al, 2020 ; Lawn, et al, 2020 ; Bebee, et al, 2021 ; Bonn-Miller, et al, 2021 ; Crippa, et al, 2021 )…”

Section: Resultsunclassified

Cannabis for Medical Use: Analysis of Recent Clinical Trials in View of Current Legislation

et al. 2022

View full text Add to dashboard Cite

Cannabis has long been regarded as a recreational substance in the Western world. The recent marketing authorization of some medicinal products of industrial origin and the introduction onto the market of inflorescences for medical use mean that medical doctors can now prescribe Cannabis-based medicines in those countries which allow it. Nevertheless, there is still considerable controversy on this topic in the scientific community. In particular, this controversy concerns: the plant species to be used; the pathologies that can be treated and consequently the efficacy and safety of use; the routes of administration; the methods of preparation; the type and dosage of cannabinoids to be used; and, the active molecules of interest. As such, although medical Cannabis has been historically used, the results of currently completed and internationally published studies are inconclusive and often discordant. In light of these considerations, the aim of this work is to analyse the current legislation in countries that allow the use of medical Cannabis, in relation to the impact that this legislation has had on clinical trials. First of all, a literature search has been performed (PubMed and SciFinder) on clinical trials which involved the administration of Cannabis for medical use over the last 3 years. Of the numerous studies extrapolated from the literature, only about 43 reported data on clinical trials on medical Cannabis, with these mainly being performed in Australia, Brazil, Canada, Denmark, Germany, Israel, Netherlands, Switzerland, the United Kingdom and the United States of America. Once the reference countries were identified, an evaluation of the legislation in relation to Cannabis for medical use in each was carried out via the consultation of the pertinent scientific literature, but also of official government documentation and that of local regulatory authorities. This analysis provided us with an overview of the different legislation in these countries and, consequently, allowed us to analyse, with greater awareness, the results of the clinical trials published in the last 3 years in order to obtain general interest indications in the prosecution of scientific research in this area.

show abstract

Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Cited by 29 publications

References 30 publications

The Prevalence of Dietary Supplement Use for the Purpose of COVID-19 Prevention in Japan

The Prevalence of Dietary Supplement Use for the Purpose of COVID-19 Prevention in Japan

Anti-Microbial Activity of Phytocannabinoids and Endocannabinoids in the Light of Their Physiological and Pathophysiological Roles

Cannabis for Medical Use: Analysis of Recent Clinical Trials in View of Current Legislation

Contact Info

Product

Resources

About